2 Dirt Cheap Healthcare Stocks to Buy in July

Novo Nordisk (NVO) and Pfizer (PFE) are highlighted as deep-value large caps ahead of Q2 reports in early August, with both trading at single-digit/low-teens forward P/Es (NVO forward P/E ~14; PFE forward P/E ~8). NVO’s bull case centers on the Wegovy GLP-1 pill ramp (oral version generating $2.26B in Q1 and 65% of new US prescriptions, plus raised 2026 guidance) but risks include US pricing pressure from planned ~50% Wegovy and ~35% Ozempic list price cuts effective Jan 2027. PFE’s bull case is improving fundamentals (Q1 FY2026 revenue $14.451B, +5% YoY; adjusted EPS $0.75, fifth straight consensus beat), supported by a Vyndamax patent settlement extending US exclusivity to June 2031 and a $7.2B cost-savings plan, though risks remain around patent cliffs/pricing policy and generic/biosimilar erosion (Comirnaty -59%, Paxlovid -63%).

Analysis

Novo looks less like a simple value trade and more like a test of whether a new dosage form can extend the franchise before the 2027 U.S. pricing reset hits margins. If the oral product keeps converting patients, the market is probably underestimating duration of therapy and refill economics; if not, the current multiple is cheap for a reason. The second-order beneficiary of any NVO stumble is LLY, but the bigger signal is that obesity is shifting from a growth-at-any-price story to a volume/share war where adherence and payer access matter more than headline prescriptions.

Pfizer is a different setup: the equity is being priced as if the COVID runoff is still the dominant driver, but the real question is whether management can convert the Vyndamax clarity plus cost saves into stable FCF while pipeline assets de-risk. The balance sheet limits enthusiasm for aggressive capital return, so the stock likely re-rates only if Q2 shows that non-COVID growth can offset the drag without another guide-down. A miss on EPS or any sign that 2026 study readouts are slipping would quickly turn the dividend story into a value trap narrative.

Contrarian view: the market may be over-discounting known headwinds and underpricing how much of the bad news is already in the multiple. NVO offers the cleaner upside convexity into August because expectations are low but the catalyst is binary; PFE is the safer carry trade, but with less obvious upside unless earnings convince investors the pipeline is self-funding. Falsifiers are straightforward: NVO losing U.S. oral share momentum into Q2, or PFE missing the implied path to full-year EPS and FCF coverage.

Key Decisions for Investors

• Go long NVO into the Aug. 5 print via a Sept/Dec call spread; risk/reward favors upside if oral GLP-1 uptake keeps compounding, with the thesis broken if Q2 shows slowing new-script share or any reduction in 2026 guidance.
• Add to PFE on any post-earnings weakness below ~$23, treating it as an income-plus-stability position; the setup is attractive as long as 2026 EPS stays within the $2.80-$3.00 band and net debt/EBITDA does not worsen beyond ~3.5x.
• Pair trade: long PFE / short XBI for 1-3 months to express preference for cash-flow visibility over unprofitable biotech duration risk; this works best if rates stay higher-for-longer and clinical readouts remain binary.
• Set an alert on NVO if U.S. obesity prescription share rolls over or gross-to-net worsens ahead of the 2027 price cuts; that would argue for taking profits quickly, as the market will reprice the franchise from growth to regulated utility economics.